Literature DB >> 9010274

IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.

P Doré1, E Lelièvre, F Morel, A Brizard, M Fourcin, C Clemént, P Ingrand, L Daneski, H Gascan, J Wijdenes, J Gombert, J L Preud'homme, J C Lecron.   

Abstract

IL-6, soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) levels were measured in sera and pleural effusions from 42 patients with metastatic carcinoma, non-Hodgkin's lymphoma, tuberculosis, cardiac failure and miscellaneous diseases. Pleural IL-6 levels measured by ELISA were very high in all patient groups (mean 34.8 +/- 15.3 ng/ml) without significant difference according to diseases. IL-6 was shown to be biologically active in a proliferative assay. Serum IL-6 levels were low (0.049 +/- 0.014 ng/ml) and did not correlate with pleural fluid levels. Pleural IL-6 levels correlated with the number of polymorphonuclear cells in pleural fluid (P < 0.03). Pleural sIL-6R levels (76 +/- 8 ng/ml) were always lower than serum levels (196 +/- 12 ng/ml; P < 0.0001) but correlated with them (P < 0.01). Pleural sIL-6R and albumin levels correlated (P < 0.01), suggesting a transudation of sIL-6R from the serum. Pleural sgp130 levels (10.9 +/- 1.0 ng/ml) were lower than serum levels (24.6 +/- 2.8 ng/ml; P < 0.002). After gel filtration of pleural fluid, the bulk of IL-6 (> 90%) was recovered in a 15,000-30,000 fraction, corresponding to the expected mol. wt of free IL-6. These results suggest a production and a sequestration of IL-6 in the pleural cavity in all studied conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010274      PMCID: PMC1904539          DOI: 10.1046/j.1365-2249.1997.d01-889.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  4 in total

1.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Treatment of malignant pleural effusions: the case for localized immunotherapy.

Authors:  Albert D Donnenberg; James D Luketich; Rajeev Dhupar; Vera S Donnenberg
Journal:  J Immunother Cancer       Date:  2019-04-18       Impact factor: 13.751

3.  Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.

Authors:  Vera S Donnenberg; Patrick L Wagner; James D Luketich; David L Bartlett; Albert D Donnenberg
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

4.  Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Authors:  Albert D Donnenberg; James D Luketich; Vera S Donnenberg
Journal:  Oncotarget       Date:  2019-11-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.